Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Non-Current Assets (2016 - 2025)

Neurocrine Biosciences (NBIX) has disclosed Non-Current Assets for 15 consecutive years, with $2.1 billion as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Non-Current Assets rose 5.76% year-over-year to $2.1 billion, compared with a TTM value of $8.4 billion through Dec 2025, up 20.77%, and an annual FY2025 reading of $2.1 billion, up 5.76% over the prior year.
  • Non-Current Assets was $2.1 billion for Q4 2025 at Neurocrine Biosciences, roughly flat from $2.1 billion in the prior quarter.
  • Across five years, Non-Current Assets topped out at $2.1 billion in Q2 2025 and bottomed at $761.0 million in Q1 2021.
  • Average Non-Current Assets over 4 years is $1.5 billion, with a median of $1.6 billion recorded in 2023.
  • The sharpest move saw Non-Current Assets soared 192.62% in 2021, then rose 5.76% in 2025.
  • Year by year, Non-Current Assets stood at $1.0 billion in 2021, then skyrocketed by 62.55% to $1.6 billion in 2023, then grew by 21.26% to $2.0 billion in 2024, then increased by 5.76% to $2.1 billion in 2025.
  • Business Quant data shows Non-Current Assets for NBIX at $2.1 billion in Q4 2025, $2.1 billion in Q3 2025, and $2.1 billion in Q2 2025.